TOULOUSE, France & LAKELAND, Mich.–(BUSINESS WIRE)–ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only recombinant apoA-I, is pleased to announce the appointment of Dr. Rob Scott as Chief Medical Officer and Head of R&D with immediate effect.
Cyrille Tupin, CEO of ABIONYX Pharma, commented: “We are excited to welcome Rob to our team just before the start of the J.P. Morgan Healthcare annual conference in San Francisco. As we develop our portfolio of clinical stage assets based on our unique apoA-I platform, Rob will bring us a wealth of experience to accelerate our programs. I look forward to working with Rob to transform ABIONYX Pharma into a successful biotech company focused on sepsis and other critical indications based on the only recombinant apoA-I in the industry.”
Dr. Rob Scott commented: “I am delighted to be joining this next generation biotech, especially at a time of great momentum with the Company’s latest outstanding Phase 2a results in sepsis. I look forward to working with the team to design and execute the pivotal approval program as ABIONYX continues to advance its exciting biodrug candidate through the clinical development and partnership process.”
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines in diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I -based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in sepsis and critical care.